reports
- Research Department
INFORME DIARIO 12 FEBRERO + RDOS. ESPAÑA Y EUROPA 4T’25. IDEAS DESTACA...
COMPAÑÍAS QUE APARECEN EN EL INFORME: EUROPA: AB INBEV, AHOLD DELHAIZE, ASML, DEUTSCHE TELEKOM, ESSILORLUXOTTICA, MERCEDES BENZ GROUP, SANOFI. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’25 que se publicarán en España y Europa en los próximos días. El dato de empleo en EE.UU. agita los mercados Jornada de más a menos en las bolsas europeas, que ...
Press Release: Belén Garijo to become Chief Executive Officer of Sanof...
Press Release: Belén Garijo to become Chief Executive Officer of Sanofi Belén Garijo to become Chief Executive Officer of Sanofi Paris, February 12, 2026. Sanofi's Board of Directors met on February 11, 2026, and decided not to renew the Director mandate of Paul Hudson. As a result, Paul Hudson’s last day as Chief Executive Officer will be on February 17, 2026 at the end of business. The Board thanks him for his valuable contributions to the transformation and development of the Group over the last six years. Following the proposal of the Appointments Committee, the Board of Directors app...
Communiqué de presse : Belén Garijo nommée Directrice générale de Sano...
Communiqué de presse : Belén Garijo nommée Directrice générale de Sanofi Belén Garijo nommée Directrice générale de Sanofi Paris, le 12 février 2026. Le Conseil d’administration de Sanofi s’est réuni le 11 février 2026 et a décidé de ne pas renouveler le mandat d’administrateur de Paul Hudson. Par conséquent, Paul Hudson quittera ses fonctions de Directeur général le 17 février 2026 au soir. Le Conseil le remercie pour sa contribution significative à la transformation et au développement du Groupe au cours des six dernières années. Sur proposition du Comité des nominations, le Conseil d’a...
Sanofi: Information concerning the total number of voting rights and s...
Sanofi: Information concerning the total number of voting rights and shares – January 2026 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,438,854,192Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry u...
Sanofi: Informations relatives au nombre de droits de vote et d'action...
Sanofi: Informations relatives au nombre de droits de vote et d'actions – JANVIER 2026 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 438 854 192 euros Siège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris Date Nombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris actio...
Communiqué de presse : Sanofi finalise l’acquisition de Dynavax
Communiqué de presse : Sanofi finalise l’acquisition de Dynavax Sanofi finalise l’acquisition de Dynavax Paris, le 10 février 2026. Sanofi a annoncé aujourd’hui avoir finalisé l’ (Dynavax). L’acquisition comprend le vaccin contre l’hépatite B pour adultes de Dynavax, HEPLISAV-B, actuellement commercialisé aux États-Unis et qui se distingue par son schéma vaccinal à deux doses administrées sur un mois. Elle comprend également le vaccin candidat contre le zona de Dynavax (Z-1018), actuellement en phase 1/2 d’essais cliniques, ainsi que d’autres projets de vaccins en développement. Cette ac...
Press Release: Sanofi completes the acquisition of Dynavax
Press Release: Sanofi completes the acquisition of Dynavax Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the (Dynavax). The acquisition includes Dynavax’s adult hepatitis B vaccine HEPLISAV-B, which is currently marketed in the US and is differentiated by its two-dose regimen over one month. It also includes Dynavax’s shingles vaccine candidate (Z-1018), which is currently in phase 1/2 studies, and additional vaccine pipeline projects. This acquisition augments Sanofi’s presence in adult immunization by bringing togethe...
Sacyr S.A.: 1 director
A director at Sacyr S.A. sold 1,000,000 shares at 3.948EUR and the significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Press Release: Sanofi’s rilzabrutinib designated breakthrough therapy ...
Press Release: Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia Rilzabrutinib is the first and only investigational BTKi for warm autoimmune hemolytic anemia to be designated Breakthrough Therapy by the FDA Rilzabrutinib helps address complex immune-system dysregulation through multi-immune modulationRilzabrutinib holds global regulatory designations acr...
Communiqué de presse: Le rilzabrutinib de Sanofi a été désigné comme t...
Communiqué de presse: Le rilzabrutinib de Sanofi a été désigné comme thérapie innovante aux États-Unis et comme médicament orphelin au Japon pour le traitement de l’anémie hémolytique auto-immune à anticorps chauds Le rilzabrutinib de Sanofi a été désigné comme thérapie innovante aux États-Unis et comme médicament orphelin au Japon pour le traitement de l’anémie hémolytique auto-immune à anticorps chauds Le rilzabrutinib est le premier et le seul BTKi expérimental pour l’’anémie hémolytique auto-immune à anticorps chauds à être désigné comme thérapie innovante par la FDA. Le rilzabrutinib...
- Luis Arredondo
INFORME SECTORIAL AUTOPISTAS EUROPA: SEGUIMOS VIENDO CATALIZADORES (AN...
Seguimos viendo catalizadores. Nuestra favorita es Ferrovial. A pesar de un entorno de crecimiento económico limitado e inflación a la baja, seguimos viendo catalizadores. Ferrovial (P.O. 65,0 euros/acc; +13% potencial) es nuestra favorita por las favorables perspectivas de sus Managed Lanes y 407ETR (especialmente a nivel de tarifas), su mayor sensibilidad a tipos y mejor posicionamiento de cara a la licitación de Managed Lanes. En Sacyr (P.O. 4,60 euros/acc; +15% potencial) estamos positivos p...
- Research Department
IBERIAN DAILY 05 FEBRUARY + 4Q’25 RESULTS. PREVIEWS (ANÁLISIS BANCO SA...
NEWS SUMMARY: ARCELORMITTAL, HIGHWAY SECTOR, IAG, INDRA, SANTANDER. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 4Q’25 results to be released over the coming days in Spain. Ibex continues to climb It was a positive session for European stock markets thanks to business results and despite mounting tension in Iran and the drops in the technology sector. In the STOXX 600, Chemi...
- Christophe-Raphaël Ganet
- Emmanuel Matot
- Thomas Zlowodzki
ACN ACCENTURE PLC CLASS A
INF INFOTEL SA
SCR SCOR SE
ASY ASSYSTEM SA
SWP SWORD GROUP SE
AUB AUBAY SA
VLS VALNEVA SE
ATE ALTEN SA
TPE PVA TEPLA AG
NEX NEXANS SA
CAP CAPGEMINI SE
SOI SOITEC SA
MTELEKOM MAGYAR TELEKOM TELECOMMUNICATIONS
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
AALB AALBERTS N.V.
MELE MELEXIS NV
ALSN ALSO HOLDING AG
ECONT ECONOCOM GROUP SE CLASS D
UNI UNICAJA BANCO S.A.
NKT NKT A/S
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
TOM2 TOMTOM NV
NA9 NAGARRO
HGEA HGEARS AG
ALVGO VOGO SA
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
- Christophe-Raphaël Ganet
- Emmanuel Matot
- Thomas Zlowodzki
ACN ACCENTURE PLC CLASS A
INF INFOTEL SA
SCR SCOR SE
ASY ASSYSTEM SA
SWP SWORD GROUP SE
AUB AUBAY SA
VLS VALNEVA SE
ATE ALTEN SA
TPE PVA TEPLA AG
NEX NEXANS SA
CAP CAPGEMINI SE
SOI SOITEC SA
MTELEKOM MAGYAR TELEKOM TELECOMMUNICATIONS
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
AALB AALBERTS N.V.
MELE MELEXIS NV
ALSN ALSO HOLDING AG
ECONT ECONOCOM GROUP SE CLASS D
UNI UNICAJA BANCO S.A.
NKT NKT A/S
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
TOM2 TOMTOM NV
NA9 NAGARRO
HGEA HGEARS AG
ALVGO VOGO SA
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
- Benoit Valleaux
- Steven Gould
- Benoit Valleaux
- Steven Gould
- Javier Esteban
UNICAJA: 4Q’25 RESULTS (ANÁLISIS BANCO SABADELL)
4Q'25 vs. 4Q'24 Results NII: € 378 M (-0.8% vs. -2.5% BS(e) and -2.3% consensus); Total Revenues: € 521 M (+0% vs. -2.5% BS(e) and -1.9% consensus); Operating Income: € 278 M (-4.5% vs. -7.9% BS(e) and -7.7% consensus); Net Profit: € 130 M (+5.9% vs. +16.8% BS(e) and +19.2% consensus); 4Q'25 vs. 3Q'25 Results NII: € 378 M (+0.8% vs. -1% BS(e) and -0.7% consensus); Total Revenues: € 521 M (+1.3% vs. -1.3% BS(e) and -0.8% consensus); Operating Income: € 278 M (+1% vs. -2.6% BS(e) and -2.4% consens...
- Javier Esteban
UNICAJA: RDOS. 4T’25 (ANÁLISIS BANCO SABADELL)
Rdos. 4T'25 vs 4T'24: M. Intereses: 378 M euros (-0,8% vs -2,5% BS(e) y -2,3% consenso); M. Bruto: 521 M euros (+0% vs -2,5% BS(e) y -1,9% consenso); M. Neto: 278 M euros (-4,5% vs -7,9% BS(e) y -7,7% consenso); BDI: 130 M euros (+5,9% vs +16,8% BS(e) y +19,2% consenso). Rdos. 4T'25 vs 3T'25: M. Intereses: 378 M euros (+0,8% vs -1% BS(e) y -0,7% consenso); M. Bruto: 521 M euros (+1,3% vs -1,3% BS(e) y -0,8% consenso); M. Neto: 278 M euros (+1% vs -2,6% BS(e) y -2,4% consenso); BDI: 130 M euros (...
- Research Department
INFORME DIARIO 03 FEBRERO + RDOS. ESPAÑA Y EUROPA 4T’25. PREVIEWS (ANÁ...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: AEDAS HOMES, INDRA, MELIÁ, TELEFÓNICA, UNICAJA. EUROPA: INTESA SANPAOLO, UNICREDIT. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’25 que se publicarán en España y Europa en los próximos días. El Ibex alcanza los 18.000 puntos Jornada de menos a más en las bolsas europeas, con el Ibex liderando de nuevo...
- Research Department
IBERIAN DAILY 03 FEBRUARY + 4Q’25 RESULTS. PREVIEWS (ANÁLISIS BANCO SA...
NEWS SUMMARY: AEDAS HOMES, INDRA, MELIÁ, UNICAJA, TELEFÓNICA. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 4Q’25 results to be released over the coming days in Spain. Ibex hits 18,000 points European stock markets saw an increasing performance, with the Ibex leading gains again, climbing more than +1.0% where the volatility of metals continued after the election of K. Warsh ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.